Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. Methods: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. Results: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). Conclusions: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS.
Abstract
Background/Aims: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. Methods: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. Results: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). Conclusions: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS.
참고문헌 (40)
- Ross R., "Atherosclerosis: an inf lammatory disease", N Engl J Med, 340, pp.115~126 (1999)
- Libby P., "Inf lammation and cardiovascular disease mechanisms", Am J Clin Nutr, 83, pp.456~460 (2006)
- Li JJ., "Inflammation: an important mechanism for different clinical entities of coronary artery diseases", Chin Med J, 118, pp.1817~1826 (2005)
- Myllarniemi M, "Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation", FASEB J, 11, pp.1119~1126 (1997)
- Libby P, "Inflammation and atherosclerosis", Circulation, 105, pp.1135~1143 (2002)
- Brauer PR., "MMPs: role in cardiovascular development and disease", Front Biosci, 11, pp.447~478 (2006)
- Schonbeck U, "CD40 signaling and plaque instability", Circ Res, 89, pp.1092~1103 (2001)
- Uzui H, "Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inf lammatory cytokines", Circulation, 106, pp.3024~3030 (2002)
- Lacraz S, "Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4", J Clin Invest, 90, pp.382~388 (1992)
- Lijnen HR., "Metalloproteinases in development and progression of vascular disease", Pathophysiol Haemost Thromb, 33, pp.275~281 (2003)
- Hirohata S, "Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction", Heart, 78, pp.278~284 (1997)
- Kai H, "Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes", J Am Coll Cardiol, 32, pp.368~372 (1998)
- Etoh T, "Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs", Am J Physiol Heart Circ Physiol, 281, pp.987~994 (2001)
- Creemers EE, "Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?", Circ Res, 89, pp.201~210 (2001)
- Dinh W, "Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction", Int Heart J, 50, pp.421~431 (2009)
- Schmitz J, "IL-33, an interleukin- 1-like cytokine that signals via the IL-1 receptorrelated protein ST2 and induces T helper type 2-associated cytokines", Immunity, 23, pp.479~490 (2005)
- Bartunek J, "Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load", J Am Coll Cardiol, 52, pp.2166~2174 (2008)
- Kuchler AM, "Nuclear interleukin- 33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinf lammatory activation", Am J Pathol, 173, pp.1229~1242 (2008)
- Sanada S, "IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system", J Clin Invest, 117, pp.1538~1549 (2007)
- Miller AM, "IL-33 reduces the development of atherosclerosis", J Exp Med, 205, pp.339~346 (2008)
- Daugherty A, "T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation", Circ Res, 90, pp.1039~1040 (2002)
- Laurat E, "In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice", Circulation, 104, pp.197~202 (2001)
- Pinderski LJ, "Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptordeficient mice by altering lymphocyte and macrophage phenotypes", Circ Res, 90, pp.1064~1071 (2002)
- Hamm CW, "ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)", Eur Heart J, 32, pp.2999~3054 (2011)
- Shah PK, "Human monocytederived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture", Circulation, 92, pp.1565~1569 (1995)
- Kim SH, "TWEAK can induce pro-inf lammatory cytokines and matrix metalloproteinase- 9 in macrophages", Circ J, 68, pp.396~399 (2004)
- Kalela A, "Serum matrix metalloproteinase- 9 concentration in angiographically assessed coronary artery disease", Scand J Clin Lab Invest, 62, pp.337~342 (2002)
- Kaden JJ, "Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction", Cardiology, 99, pp.140~144 (2003)
- Higo S, "Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection", Circ J, 69, pp.1180~1185 (2005)
- Romanic AM, "Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit", Life Sci, 68, pp.799~814 (2001)
- Kameda K, "Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture", Circ J, 70, pp.673~678 (2006)
- van den Borne SW, "Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction", Cardiovasc Pathol, 18, pp.37~43 (2009)
- Inokubo Y, "Plasma levels of matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome", Am Heart J, 141, pp.211~217 (2001)
- Tziakas DN, "Nterminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction", Am J Cardiol, 96, pp.31~34 (2005)
- Nanni S, "Matrix metalloproteinases in premature coronary atherosclerosis: inf luence of inhibitors, inf lammation, and genetic polymorphisms", Transl Res, 149, pp.137~144 (2007)
- Tan J, "Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase- 9, and tissue inhibitor of metalloproteinase- 1 in patients with acute ST-segment elevation myocardial infarction", Clin Cardiol, 31, pp.413~418 (2008)
- Weinberg EO, "Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction", Circulation, 106, pp.2961~2966 (2002)
- McLaren JE, "IL-33 reduces macrophage foam cell formation", J Immunol, 185, pp.1222~1229 (2010)
- Mehta JL, "Interactive role of infection, inf lammation and traditional risk factors in atherosclerosis and coronary artery disease", J Am Coll Cardiol, 31, pp.1217~1225 (1998)
- Shishehbor MH, "Inflammation and atherosclerosis", Curr Atheroscler Rep, 6, pp.131~139 (2004)